[Preliminary study on isoniazid-epiroprim combination in a tuberculosis murine model].

Area of Science:

• Microbiology
• Pharmacology
• Infectious Diseases

Background:

• Tuberculosis remains a significant global health challenge.
• Drug resistance necessitates the development of novel therapeutic strategies.
• Isoniazid is a first-line antituberculosis drug, but resistance is a growing concern.

Purpose of the Study:

• To evaluate the efficacy of epiroprim alone and in combination with isoniazid against Mycobacterium tuberculosis.
• To assess the therapeutic potential of the isoniazid-epiroprim combination in a murine model of tuberculosis.

Main Methods:

• A murine model of tuberculosis was established using C57Bl/6 mice infected with Mycobacterium tuberculosis strain H37Rv.
• Mice were divided into four groups and treated with either isoniazid, epiroprim, isoniazid plus epiroprim, or a control.
• Bacterial titres in the spleen and lungs were determined after a three-week treatment period.

Main Results:

• The combination of isoniazid and epiroprim demonstrated higher efficacy in reducing bacterial load in mouse lungs compared to isoniazid monotherapy.
• Epiroprim alone showed some activity, but was less effective than the combination therapy.
• All Mycobacterium tuberculosis isolates obtained were sensitive to isoniazid.

Conclusions:

• The combination of isoniazid and epiroprim appears to be a promising therapeutic approach for murine pulmonary tuberculosis.
• Further research is warranted to explore the clinical applicability of this drug combination in human tuberculosis treatment.
• The observed sensitivity of Mycobacterium tuberculosis to isoniazid in this model highlights the importance of continued susceptibility testing.